News stories about BioScrip (NASDAQ:BIOS) have been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioScrip earned a news impact score of 0.15 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.4372461705285 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Zacks: Analysts Expect BioScrip Inc (BIOS) Will Announce Earnings of -$0.08 Per Share (americanbankingnews.com)
- BioScrip, Inc. (BIOS) – Well known Mover to Watch – Nasdaq Fortune (press release) (nasdaqfortune.com)
- BioScrip (BIOS) Rating Reiterated by SunTrust Banks (americanbankingnews.com)
- Analysts’ Recommendations Roundup: Bioscrip Inc (BIOS) – ExpertGazette (expertgazette.com)
- BioScrip, Inc. (NASDAQ:BIOS) – Stock to Watch – Nasdaq Journal (press release) (nasdaqjournal.com)
BIOS has been the topic of several analyst reports. ValuEngine upgraded BioScrip from a “strong sell” rating to a “sell” rating in a report on Thursday, November 9th. SunTrust Banks restated a “buy” rating and set a $3.00 price objective on shares of BioScrip in a report on Friday, November 3rd. Finally, Zacks Investment Research downgraded BioScrip from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $3.80.
BioScrip (NASDAQ:BIOS) last issued its quarterly earnings results on Thursday, November 2nd. The company reported ($0.12) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.02). The firm had revenue of $198.70 million during the quarter, compared to analyst estimates of $202.91 million. During the same period last year, the business earned ($0.12) EPS. The company’s revenue was down 11.5% on a year-over-year basis. equities analysts anticipate that BioScrip will post -0.63 earnings per share for the current fiscal year.
In other news, CEO Daniel E. Greenleaf purchased 15,000 shares of the stock in a transaction dated Thursday, November 9th. The stock was acquired at an average cost of $2.03 per share, for a total transaction of $30,450.00. Following the acquisition, the chief executive officer now owns 31,000 shares of the company’s stock, valued at $62,930. The acquisition was disclosed in a filing with the SEC, which is available at this link. 0.80% of the stock is currently owned by insiders.
TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/12/24/bioscrip-bios-getting-somewhat-positive-media-coverage-study-shows.html.
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
What are top analysts saying about BioScrip? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BioScrip and related companies.